Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dual-targeted CAR T shows ‘clinical signal’ in NHL

Key clinical point: A dual-targeted, locally manufactured, anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was safe and has produced ongoing complete responses.

Major finding: Of 12 patients treated to date, 7 have maintained complete responses for times ranging up to 19 months.

Study details: Report on a phase 1 study including 12 patients with relapsed/refractory non-Hodgkin lymphomas.

Disclosures: Dr. Hari reported disclosures related to Juno, Kite, Spectrum, Janssen, Takeda, Celgene, and BMS. Several study coauthors were employed by Lentigen Technology, a Miltenyi Biotec Company.

Citation:

Shah NN et al. TCT 2019, Abstract 80.